Literature DB >> 10767857

Immunotherapy of AML: future directions.

M W Lowdell1, M B Koh.   

Abstract

Immunotherapy in the form of allogeneic GvL has been curing AML patients for nearly 30 years but our understanding of the mechanisms has been poor. Our rapidly evolving understanding of the human immune system and the concomitant technical developments in ex vivo cell manipulation, the vision of funding bodies, the dedication of clinical and research staff, and above all the commitment of our patients, promise substantial progress in the treatment of this disease in the year 2000 and beyond.

Entities:  

Mesh：

Year:  2000        PMID： 10767857      PMCID： PMC1731053          DOI： 10.1136/jcp.53.1.49

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


  55 in total

1.  CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.

Authors:  R R French; H T Chan; A L Tutt; M J Glennie
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

Review 2.  Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy.

Authors:  E Goulmy
Journal:  Immunol Rev       Date:  1997-06       Impact factor: 12.988

3.  Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.

Authors:  J S Miller; J Tessmer-Tuck; B A Pierson; D Weisdorf; P McGlave; B R Blazar; E Katsanis; C Verfaillie; J Lebkowski; J Radford; L J Burns
Journal:  Biol Blood Marrow Transplant       Date:  1997-04       Impact factor: 5.742

4.  Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes.

Authors:  L Zitvogel; A Regnault; A Lozier; J Wolfers; C Flament; D Tenza; P Ricciardi-Castagnoli; G Raposo; S Amigorena
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

5.  Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.

Authors:  E M Sotomayor; I Borrello; E Tubb; F M Rattis; H Bien; Z Lu; S Fein; S Schoenberger; H I Levitsky
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

6.  Transplantation of anergic histoincompatible bone marrow allografts.

Authors:  E C Guinan; V A Boussiotis; D Neuberg; L L Brennan; N Hirano; L M Nadler; J G Gribben
Journal:  N Engl J Med       Date:  1999-06-03       Impact factor: 91.245

7.  CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses.

Authors:  B R Blazar; P A Taylor; R J Noelle; D A Vallera
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

8.  Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation.

Authors:  J H Falkenburg; L M Faber; M van den Elshout; S A van Luxemburg-Heijs; A Hooftman-den Otter; W M Smit; P J Voogt; R Willemze
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-11

9.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

Authors:  H J Kolb; A Schattenberg; J M Goldman; B Hertenstein; N Jacobsen; W Arcese; P Ljungman; A Ferrant; L Verdonck; D Niederwieser; F van Rhee; J Mittermueller; T de Witte; E Holler; H Ansari
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

10.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.

Authors:  C Bonini; G Ferrari; S Verzeletti; P Servida; E Zappone; L Ruggieri; M Ponzoni; S Rossini; F Mavilio; C Traversari; C Bordignon
Journal:  Science       Date:  1997-06-13       Impact factor: 47.728
View more
  6 in total

1.  Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.

Authors:  Marc Buyse; Pierre Squifflet; Beverly J Lange; Todd A Alonzo; Richard A Larson; Jonathan E Kolitz; Stephen L George; Clara D Bloomfield; Sylvie Castaigne; Sylvie Chevret; Didier Blaise; Dominique Maraninchi; Kathryn J Lucchesi; Tomasz Burzykowski
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

2.  Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells.

Authors:  Johan Aurelius; Anna Martner; Mats Brune; Lars Palmqvist; Markus Hansson; Kristoffer Hellstrand; Fredrik B Thoren
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

3.  Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission.

Authors:  Qiang Zeng; Zhigang Liu; Bing Xiang
Journal:  Ann Hematol       Date:  2022-05-16       Impact factor: 4.030

Review 4.  Immunological weapons against acute myeloid leukaemia.

Authors:  Joanna Galea-Lauri
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

5.  Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia.

Authors:  Edward Abadir; Pablo A Silveira; Robin E Gasiorowski; Murari Ramesh; Adelina Romano; Ahmed H Mekkawy; Tsun-Ho Lo; Karieshma Kabani; Sarah Sutherland; Geoffrey A Pietersz; P Joy Ho; Christian E Bryant; Stephen R Larsen; Georgina J Clark
Journal:  Blood Adv       Date:  2020-04-14

6.  Maintenance Therapy With Interleukin-2 for Childhood AML: Results of ELAM02 Phase III Randomized Trial.

Authors:  Arnaud Petit; Stéphane Ducassou; Thierry Leblanc; Marlène Pasquet; Alexandra Rousseau; Christine Ragu; Marine Cachanado; Brigitte Nelken; Yves Bertrand; Gérard Michel; Virginie Gandemer; Wendy Cuccuini; Odile Fenneteau; Hélène Lapillonne; Anne Auvrignon; André Baruchel; Guy Leverger
Journal:  Hemasphere       Date:  2018-11-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.